View
111
Download
0
Category
Tags:
Preview:
Citation preview
1IBM Technology Day 2013, Keynote B. Dubuis11.6.2013
Click to edit Master title style
© BD, ROI© 2013 IBM Corporation
Biotech, Medtech and Bioconvergence
Dr. Benoit Dubuis, President BioAlps & Inartis-Network, Executive Director Campus Biotech
17.09.2014
HEALTH CARE “Medical revolution and new technologies”
The challenges
Towards bioconvergence
Our contribution
Anticipate the Future
HEALTH CARE “Medical revolution and new technologies”
The challenges
Towards bioconvergence
Our contribution
Anticipate the Future
Crossing Visions14.04.23 | 4
MAJOR CHALLENGESIN HEALTHCARE
Therapeutic challenges
Demographics
Cost
Access
Variation in clinical practice
Inefficient use of information
Fragmented care versus integrated care
Duplication, defensive medicine & waste
Protracted adoption of innovation
Crossing Visions14.04.23 | 5
CAUSESOF DEATH
Crossing Visions14.04.23 | 62
DEMOGRAPHICS:WE LIVELONGER
Life
Exp
ecta
ncy
at B
irth
Benchmark: Life expectancy in imperial Rome was ~ 30 years
1900 1950 2010 2050
CH: 80.5
CH: 84.7
Age 60 – 2 BillionAge 80 – 380 MillionAge 100 – 2 Million
Benchmark: Life expectancy in imperial Rome was ~ 30 years
Age 60 – 2 BillionAge 80 – 380 MillionAge 100 – 2 Million
Crossing Visions14.04.23 | 7
HEALTH CARECOSTS
3
Crossing Visions14.04.23 | 8
THE BURDEN OFCHRONIC DISEASES
Healthcare spending for people with chronic conditions
Nearly half of us will havechronic conditions by 2030:
DiabetesNeurodegenerative DiseaseObesityHypertensionArthritisAtherosclerosisStrokeCancerDegenerative Joint diseaseDegenerative Spine DiseaseObstructive Lung Disease
Healthcare spending for people without chronic conditions
Chronic conditionsaccount for 83% of health care spending4
NEW NEEDS INNEURO-ENGINEERING
5
Crossing Visions14.04.23 | 10
TOWARDHEALTHIER
LIFEPast model
Present model
Compressed morbidity model
Healthy life
Healthy life
DiseaseDisability
DiseaseDisability
Healthy life Life years gainedDiseaseDisability
11IBM Technology Day 2013, Keynote B. Dubuis11.6.2013
Click to edit Master title style
MEDTECH “Medical revolution and new technologies”
The challenges
Towards Bioconvergence
Our contribution
Anticipate the Future
Crossing Visions14.04.23 | 12
CHANGING FOCUSON HEALTH CARE
Technology convergence
Pharmacogenomics
3P medicine
Translational medicine
Wireless Health
TOWARDS ANINTEGRATED HEALTH SYSTEM
Rx 2009
Crossing Visions14.04.23 | 14
INNOVATION BYBIOCONVERGENCE
Crossing Visions14.04.23 | 15
EXPLORE INTERFACES
Crossing Visions14.04.23 | 16
NEXT GENERATIONPLATFORM TECHNOLOGIES
NEWPRODUCTS
NEWSOLUTIONS
Crossing Visions14.04.23 | 18
THE STRENGTHOF THE
NETWORKCLINICAL CENTERS
ACADEMIC CENTERS
COREFACILITIES
INDUSTRY START-UPS
191/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
Interdisciplinarity (science driven)
What is a Stent
A small, mesh-like device made of metal
Acts as a support or scaffold, in keeping the vessel open
Stent helps to improve blood flow to the heart muscle and reduce
the pain of angina
80% of patients who have balloon angioplasty will have a stent
placed as well.
History
Percutaneous transluminal coronary angioplasty (PTCA) by
Gruntzig in 1977
Puel and Sigwart, in 1986, deployed the first coronary stent to act
as a scaffold
In 2001, drug-eluting stents (DES) were introduced as a strategy
to minimize restenosis
Types
Bare metal stents: Traditional method
May have an increased rate of
re-narrowing due to growth of scar
tissue in the stent, a condition called
Restenosis.
Drug-eluting stents:
Combat Restenosis
Coated with medications that are slowly released
to block the body's ability to form scar tissue
around the stent. The medication is delivered
directly to the site of the artery blockage.
23IBM Technology Day 2013, Keynote B. Dubuis11.6.2013
Click to edit Master title style
MEDTECH “Medical revolution and new technologies”
The challenges
Towards an integrated health system
Our contribution
Innovation: The New Currency of
Competition
Crossing Visions14.04.23 | 24
MICRO / NANO CLUSTER
BIOCLUSTER
A UNIQUE HUBFOR MEDTECH & BIOTECH
WORLD-CLASSACADEMIC
INSTITUTIONS
Generate KnowledgeCreate Opportunities
261/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
'evolutionary developmental biology'
Electronic health record'
Access to tools and knowledge
271/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
The shift to patient-empowering, information-leveraging technologies
“PI” (patient-empowering and information-leveraging) technologies
291/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
Molecular and personalized medicine
Proficient use of Information (e.health)
Genomic & physiology
Access, Cost and Quality of care
301/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
INNOVATIONThe New Currency of Competition
311/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
EXPLORE NEW AVENUES
321/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
WHEREHISTORY WRITES
TowardsCampus Biotech
331/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
WHEREHISTORY WRITESENSURING THAT
HISTORY GOES ON
Crossing Visions14.04.23 | 35
NEWPATHS
361/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
371/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
ACCELERATETECH TRANSFER
381/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
SupportTechnology Transfer
391/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
INARTIS NETWORK, NTN
R&D Projects(CTI)
R&D Projects(CTI)
Workshops
EventsWorkshops
Events
NetworkingNetworking
40IBM Technology Day 2013, Keynote B. Dubuis11.6.2013
Click to edit Master title style
MEDTECH “Medical revolution and new technologies”
The challenges
Towards an integrated health system
Our contribution
Anticipate the Future
Crossing Visions14.04.23 | 41
750 companties25’000 employees
Crossing Visions14.04.23 | 42
Support the growthAnticipate the Future
Vitesse moyenne de croissance annuelle 95-00, 00-06Source: BAK, Basel Economics
431/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
A Successfull biocluster
EstablishedaccesstoCapital
ExperiencedBusiness and
LawFirms
Carve-Outs/Spinouts
ExperiencedEntrepreneur Innovation
Initiatives
World-ClassResearch
Institutions
ExperiencedTechnicalPeople
World-ClassBusinessSchools
PhD’s
MBA’s
Early-StageCompany
Late-StageEmerging/Public
PublicIndustryLeader
IP
CreateValuearound IP
CreateValue
C://DUBUIS, 2009
© 2014 INARTIS
© 2013 IBM Corporation
Find the slides on:
www.republic-of-innovation.ch
Dr. Benoit Dubuisbd@republic-of-innovation.ch
Recommended